The European Commission has approved an extension to the indications of Bavarian Nordic’s mpox vaccine, Imvanex, to include adolescents aged from 12 to 17 years, in a move intended to help health authorities in Africa and elsewhere tackle the spread of the disease.
The decision was taken on 19 September on the basis of a recommendation from the European Medicines Agency’s human drugs committee, the CHMP, which was announced the same day
Imvanex, which is already approved in the EU under exceptional circumstances to protect adults against smallpox, mpox and disease caused by the vaccinia virus, contains a live and highly weakened form of modified